-
2
-
-
77954595101
-
Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence
-
Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010; 4: 1-9.
-
(2010)
Patient Prefer Adherence
, vol.4
, pp. 1-9
-
-
Patti, F.1
-
3
-
-
64249093467
-
A review of disease- modifying therapies for MS: Maximizing adherence and minimizing adverse events
-
Brandes DW, Callender T, Lathi E, et al. A review of disease- modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009; 25: 77-92.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 77-92
-
-
Brandes, D.W.1
Callender, T.2
Lathi, E.3
-
4
-
-
65749088247
-
Factors that influ- ence adherence with disease-modifying therapy in MS
-
Treadaway K, Cutter G, Salter A, et al. Factors that influ- ence adherence with disease-modifying therapy in MS. J Neurol 2009; 256: 568-76.
-
(2009)
J Neurol
, vol.256
, pp. 568-76
-
-
Treadaway, K.1
Cutter, G.2
Salter, A.3
-
5
-
-
10644241482
-
Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis
-
Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 2004; 5: 357-9.
-
(2004)
Am J Clin Dermatol
, vol.5
, pp. 357-9
-
-
Soos, N.1
Shakery, K.2
Mrowietz, U.3
-
6
-
-
76149083915
-
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
-
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-26.
-
(2010)
N Engl J Med
, vol.362
, pp. 416-26
-
-
Giovannoni, G.1
Comi, G.2
Cook, S.3
-
7
-
-
76149093586
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
-
Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
-
(2010)
N Engl J Med
, vol.362
, pp. 387-401
-
-
Kappos, L.1
Radue, E.W.2
O'Connor, P.3
-
8
-
-
76149140914
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
-
Cohen J, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
-
(2010)
N Engl J Med
, vol.362
, pp. 402-15
-
-
Cohen, J.1
Barkhof, F.2
Comi, G.3
-
9
-
-
78649839271
-
A placebo- controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: Clinical efficacy and safety outcomes [abstract]
-
O'Connor P, Wolinsky J, Confavreux C, et al. A placebo- controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes [abstract]. Mult Scler 2010; 16: S23.79.
-
(2010)
Mult Scler
, vol.16
-
-
O'Connor, P.1
Wolinsky, J.2
Confavreux, C.3
-
10
-
-
27944443692
-
Cladribine for multiple sclerosis: Review and current status
-
Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5: 721-7.
-
(2005)
Expert Rev Neurother
, vol.5
, pp. 721-7
-
-
Sipe, J.C.1
-
11
-
-
0026799508
-
Cladribine (2-chlorodeoxyadenosine)
-
Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6.
-
(1992)
Lancet
, vol.340
, pp. 952-6
-
-
Beutler, E.1
-
12
-
-
0028264426
-
Cladribine in treat- ment of chronic progressive multiple sclerosis
-
Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treat- ment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
-
(1994)
Lancet
, vol.344
, pp. 9-13
-
-
Sipe, J.C.1
Romine, J.S.2
Koziol, J.A.3
-
13
-
-
0029983154
-
The treatment of chronic progressive multiple sclerosis with cladribine
-
Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 93: 1716-20.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 1716-20
-
-
Beutler, E.1
Sipe, J.C.2
Romine, J.S.3
-
14
-
-
0032908474
-
A double-blind, placebo- controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
-
Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo- controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44.
-
(1999)
Proc Assoc Am Physicians
, vol.111
, pp. 35-44
-
-
Romine, J.S.1
Sipe, J.C.2
Koziol, J.A.3
-
15
-
-
0034642247
-
Whole brain vol- ume changes in patients with progressive MS treated with cladribine
-
Filippi M, Rovaris M, Iannucci G, et al. Whole brain vol- ume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-8.
-
(2000)
Neurology
, vol.55
, pp. 1714-8
-
-
Filippi, M.1
Rovaris, M.2
Iannucci, G.3
-
16
-
-
0034194016
-
The effect of cladribine on T(1) 'black hole' changes in progressive MS
-
Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 2000; 176: 42-4.
-
(2000)
J Neurol Sci
, vol.176
, pp. 42-4
-
-
Filippi, M.1
Rovaris, M.2
Rice, G.P.3
-
17
-
-
0034646216
-
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
-
Cladribine MRI Study Group
-
Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-55.
-
(2000)
Neurology
, vol.54
, pp. 1145-55
-
-
Rice, G.P.1
Filippi, M.2
Comi, G.3
-
18
-
-
54149116366
-
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
-
Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-72.
-
(2008)
Lancet
, vol.372
, pp. 1463-72
-
-
Kappos, L.1
Gold, R.2
Miller, D.H.3
-
19
-
-
45249107267
-
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
-
Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-92.
-
(2008)
Lancet
, vol.371
, pp. 2085-92
-
-
Comi, G.1
Pulizzi, A.2
Rovaris, M.3
-
20
-
-
33645799680
-
A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
-
O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900.
-
(2006)
Neurology
, vol.66
, pp. 894-900
-
-
O'Connor, P.W.1
Li, D.2
Freedman, M.S.3
-
21
-
-
0027418515
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
-
The IFN-beta Multiple Sclerosis Study Group
-
The IFN-beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
-
(1993)
Neurology
, vol.43
, pp. 655-61
-
-
-
22
-
-
0008678962
-
Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis
-
for the Multi- ple Sclerosis Collaborative Research Group (MSCRG)
-
Jacobs LD, Cookfair DL, Rudick RA, et al., for the Multi- ple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
-
(1996)
Ann Neurol
, vol.39
, pp. 285-94
-
-
Jacobs, L.D.1
Cookfair, D.L.2
Rudick, R.A.3
-
23
-
-
74249110620
-
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multiple-center, randomized, double-blind, parallel-group placebo-controlled study [abstract no. P31]
-
for the LAQ/5062 Clinical Advisory Board and Study Group
-
Comi G, Abramsky O, Arbizu T, et al., for the LAQ/5062 Clinical Advisory Board and Study Group. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multiple-center, randomized, double-blind, parallel-group placebo-controlled study [abstract no. P31]. Mult Scler 2008; 14 (1 Suppl.): S37-8.
-
(2008)
Mult Scler
, vol.14
, Issue.1 SUPPL.
-
-
Comi, G.1
Abramsky, O.2
Arbizu, T.3
-
24
-
-
43449108927
-
-
Leustatin® (cladribine) Raritan (NJ): Centocor Ortho Biotech
-
Leustatin® (cladribine): US prescribing information. Rari- tan (NJ): Centocor Ortho Biotech, 2007.
-
(2007)
US Prescribing Information
-
-
-
25
-
-
0037214931
-
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
-
Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114-20.
-
(2003)
Cancer
, vol.97
, pp. 114-20
-
-
Montillo, M.1
Tedeschi, A.2
O'Brien, S.3
-
26
-
-
77957184066
-
Progressive multi- focal leukoencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease
-
Astrom K, Mancall EL, Richardson EP. Progressive multi- focal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease. Brain 1958; 81: 93-111.
-
(1958)
Brain
, vol.81
, pp. 93-111
-
-
Astrom, K.1
Mancall, E.L.2
Richardson, E.P.3
-
27
-
-
12344302306
-
FTY720: Mechanism of action and potential benefit in organ transplantation
-
Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004; 45: 991-7.
-
(2004)
Yonsei Med J
, vol.45
, pp. 991-7
-
-
Brinkmann, V.1
-
28
-
-
1642580757
-
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
-
Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-60.
-
(2004)
Nature
, vol.427
, pp. 355-60
-
-
Matloubian, M.1
Lo, C.G.2
Cinamon, G.3
-
29
-
-
17644365138
-
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs
-
Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-59.
-
(2005)
Annu Rev Immunol
, vol.23
, pp. 127-59
-
-
Cyster, J.G.1
-
30
-
-
3142709457
-
FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: Evidence for distinct chemokine compartments
-
Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173: 855-65.
-
(2004)
J Immunol
, vol.173
, pp. 855-65
-
-
Yopp, A.C.1
Fu, S.2
Honig, S.M.3
-
31
-
-
0037379202
-
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment
-
Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-7.
-
(2003)
J Pharmacol Exp Ther
, vol.305
, pp. 70-7
-
-
Fujino, M.1
Funeshima, N.2
Kitazawa, Y.3
-
32
-
-
3042750654
-
Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging
-
Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20: 16-24.
-
(2004)
J Magn Reson Imaging
, vol.20
, pp. 16-24
-
-
Rausch, M.1
Hiestand, P.2
Foster, C.A.3
-
33
-
-
3242683494
-
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice
-
Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuro-immunol 2004; 153: 108-21.
-
(2004)
J Neuroimmunol
, vol.153
, pp. 108-21
-
-
Webb, M.1
Tham, C.S.2
Lin, F.F.3
-
34
-
-
0037077308
-
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
-
Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-7.
-
(2002)
J Biol Chem
, vol.277
, pp. 21453-7
-
-
Brinkmann, V.1
Davis, M.D.2
Heise, C.E.3
-
35
-
-
77953211778
-
The impact of fingolimod (FTY720) in neuroimmunologic diseases: Mechanisms beyond im-munomodulation
-
Haghikia A, Gold R. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond im-munomodulation. Am J Pathol 2010; 176: 2599-601.
-
(2010)
Am J Pathol
, vol.176
, pp. 2599-601
-
-
Haghikia, A.1
Gold, R.2
-
36
-
-
77951479603
-
Oral fingolimod (FTY720) inhibits ongoing CNS autoimmunity and promotes recovery in mice with chronic experimental autoimmune encephalomyelitis [abstract no. P228]
-
Bernard F, Sablone M, Sansig G, et al. Oral fingolimod (FTY720) inhibits ongoing CNS autoimmunity and promotes recovery in mice with chronic experimental autoimmune encephalomyelitis [abstract no. P228]. Mult Scler 2009; 15 Suppl. 2: S58.
-
(2009)
Mult Scler
, vol.15
, Issue.SUPPL. 2
-
-
Bernard, F.1
Sablone, M.2
Sansig, G.3
-
37
-
-
77955799815
-
Oral fingolimod (FTY720) for relapsing multiple sclerosis
-
Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-40.
-
(2006)
N Engl J Med
, vol.355
, pp. 1124-40
-
-
Kappos, L.1
Antel, J.2
Comi, G.3
-
38
-
-
63849147004
-
Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
-
O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009; 72: 73-9.
-
(2009)
Neurology
, vol.72
, pp. 73-9
-
-
O'Connor, P.1
Comi, G.2
Montalban, X.3
-
39
-
-
76449120437
-
Phase II study of oral fin-golimod (FTY720) in multiple sclerosis: 3-year results
-
for the FTY720D2201 Study Group
-
Comi G, O'Connor P, Montalban X, et al., for the FTY720D2201 Study Group. Phase II study of oral fin-golimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010; 16: 197-207.
-
(2010)
Mult Scler
, vol.16
, pp. 197-207
-
-
Comi, G.1
O'Connor, P.2
Montalban, X.3
-
41
-
-
78649820015
-
Efficacy of the selective S1P 1/5 modulator, BAF312, in established experimental autoimmune encephalomyelitis and redistribution of S1P1 and S1P5 in the inflamed human CNS tissue [poster no. P858]
-
Oct 13-16; Gothenburg
-
Seabrook TJ, Smith P, Schweitzer A, et al. Efficacy of the selective S1P 1/5 modulator, BAF312, in established experimental autoimmune encephalomyelitis and redistribution of S1P1 and S1P5 in the inflamed human CNS tissue [poster no. P858]. 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Gothenburg.
-
(2010)
26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis
-
-
Seabrook, T.J.1
Smith, P.2
Schweitzer, A.3
-
42
-
-
78649806040
-
A phase i study to evaluate safety tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis [poster no. P991]
-
ONO-4641 Study Group Oct 13-16; Gothenburg
-
Kasper LH, Due BR, ONO-4641 Study Group. A phase I study to evaluate safety, tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis [poster no. P991]. 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Gothenburg.
-
(2010)
26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis
-
-
Kasper, L.H.1
Due, B.R.2
-
43
-
-
54349101744
-
Identification and devel- opment of new therapeutics for multiple sclerosis
-
Linker RA, Kieseier BC, Gold R. Identification and devel- opment of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29: 558-65.
-
(2008)
Trends Pharmacol Sci
, vol.29
, pp. 558-65
-
-
Linker, R.A.1
Kieseier, B.C.2
Gold, R.3
-
44
-
-
41549092261
-
Rasagiline in treatment of Parkin- son's disease
-
Nayak L, Henchcliffe C. Rasagiline in treatment of Parkin- son's disease. Neuropsychiatr Dis Treat 2008; 4: 11-20.
-
(2008)
Neuropsychiatr Dis Treat
, vol.4
, pp. 11-20
-
-
Nayak, L.1
Henchcliffe, C.2
-
45
-
-
33744819999
-
Antioxidants in multiple sclerosis: Do they have a role in therapy?
-
Carlson NG, Rose JW. Antioxidants in multiple sclerosis: do they have a role in therapy? CNS Drugs 2006; 20: 433-41.
-
(2006)
CNS Drugs
, vol.20
, pp. 433-41
-
-
Carlson, N.G.1
Rose, J.W.2
-
46
-
-
74049120922
-
New oral drugs for multiple sclerosis
-
Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci 2009; 30 Suppl. 2: S179-83.
-
(2009)
Neurol Sci
, vol.30
, Issue.SUPPL. 2
-
-
Gasperini, C.1
Ruggieri, S.2
-
47
-
-
47849083585
-
Nrf2 signaling: An adaptive re- sponse pathway for protection against environmental toxic insults
-
Osburn WO, Kensler TW. Nrf2 signaling: an adaptive re- sponse pathway for protection against environmental toxic insults. Mutat Res 2008; 659: 31-9.
-
(2008)
Mutat Res
, vol.659
, pp. 31-9
-
-
Osburn, W.O.1
Kensler, T.W.2
-
48
-
-
58649100237
-
Nrf2- regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress
-
Harveya CJ, Thimmulappaa RK, Singha A, et al. Nrf2- regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 2009; 46: 443-53.
-
(2009)
Free Radic Biol Med
, vol.46
, pp. 443-53
-
-
Harveya, C.J.1
Thimmulappaa, R.K.2
Singha, A.3
-
49
-
-
33846264538
-
Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis
-
Khor T, Huang M, Kwon K, et al. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006; 66: 11580-4.
-
(2006)
Cancer Res
, vol.66
, pp. 11580-4
-
-
Khor, T.1
Huang, M.2
Kwon, K.3
-
50
-
-
0038146898
-
Identification of the NF- E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis
-
Lee JM, Calkins MJ, Chan K, et al. Identification of the NF- E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003; 278: 12029-38.
-
(2003)
J Biol Chem
, vol.278
, pp. 12029-38
-
-
Lee, J.M.1
Calkins, M.J.2
Chan, K.3
-
51
-
-
0141621061
-
NF-E2-related factor- 2 mediates neuroprotection against mitochondrial complex i inhibitors and increased concentrations of intracellular calcium in primary cortical neurons
-
Lee JM, Shih AY, Murphy TH, et al. NF-E2-related factor- 2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003; 278: 37948-56.
-
(2003)
J Biol Chem
, vol.278
, pp. 37948-56
-
-
Lee, J.M.1
Shih, A.Y.2
Murphy, T.H.3
-
52
-
-
57649213538
-
The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration
-
Johnson JA, Johnson DA, Kraft AD, et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008; 1147: 61-9.
-
(2008)
Ann N y Acad Sci
, vol.1147
, pp. 61-9
-
-
Johnson, J.A.1
Johnson, D.A.2
Kraft, A.D.3
-
53
-
-
20744440945
-
Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo
-
Shih AY, Imbeault S, Barakauskas V, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005; 280: 22925-36.
-
(2005)
J Biol Chem
, vol.280
, pp. 22925-36
-
-
Shih, A.Y.1
Imbeault, S.2
Barakauskas, V.3
-
54
-
-
51649088304
-
Activation of Nrf2 and modulation of disease progression in EAE models by BG-12 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotec-tive modalities [abstract no. P503]
-
Lukashev M, Zeng W, Goelz S, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG-12 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotec-tive modalities [abstract no. P503]. Mult Scler 2007; 13 (2 Suppl.): S149.
-
(2007)
Mult Scler
, vol.13
, Issue.2 SUPPL.
-
-
Lukashev, M.1
Zeng, W.2
Goelz, S.3
-
55
-
-
33745162188
-
Fumaric acid esters are effective in chronic experimental autoimmune encephalo-myelitis and suppress macrophage infiltration
-
Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalo-myelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145: 101-7.
-
(2006)
Clin Exp Immunol
, vol.145
, pp. 101-7
-
-
Schilling, S.1
Goelz, S.2
Linker, R.3
-
56
-
-
33745051595
-
Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study
-
Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604-10.
-
(2006)
Eur J Neurol
, vol.13
, pp. 604-10
-
-
Schimrigk, S.1
Brune, N.2
Hellwig, K.3
-
57
-
-
78649508546
-
The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions [abstract no. P459]
-
MacManus DG, Miller DH, Kappos L, et al. The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions [abstract no. P459]. Mult Scler 2008; 14 Suppl. 2: S163.
-
(2008)
Mult Scler
, vol.14
, Issue.SUPPL. 2
-
-
MacManus, D.G.1
Miller, D.H.2
Kappos, L.3
-
58
-
-
0042413498
-
Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
-
Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
-
(2003)
Br J Dermatol
, vol.149
, pp. 363-9
-
-
Hoefnagel, J.J.1
Thio, H.B.2
Willemze, R.3
-
59
-
-
34249693512
-
German evidence-based guidelines for the treatment of psoriasis vulgaris (short version)
-
Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-38.
-
(2007)
Arch Dermatol Res
, vol.299
, pp. 111-38
-
-
Nast, A.1
Kopp, I.2
Augustin, M.3
-
60
-
-
0029838040
-
Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
-
Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900.
-
(1996)
Neurology
, vol.47
, pp. 895-900
-
-
Andersen, O.1
Lycke, J.2
Tollesson, P.O.3
-
61
-
-
0029832923
-
Treatment of secondary progressive multiple sclerosis with the immuno-modulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
-
Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immuno-modulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-6.
-
(1996)
Neurology
, vol.47
, pp. 341-6
-
-
Karussis, D.M.1
Meiner, Z.2
Lehmann, D.3
-
62
-
-
0034624942
-
Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results
-
North American Linomide Investigators
-
Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I. Trial design and clinical results. North American Linomide Investigators. Neurology 2000; 54: 1726-33.
-
(2000)
Neurology
, vol.54
, pp. 1726-33
-
-
Noseworthy, J.H.1
Wolinsky, J.S.2
Lublin, F.D.3
-
63
-
-
0036710356
-
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
-
Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163-72.
-
(2002)
J Neuroimmunol
, vol.130
, pp. 163-72
-
-
Brunmark, C.1
Runstrom, A.2
Ohlsson, L.3
-
64
-
-
4744340401
-
Laquinimod (ABR- 215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats
-
Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR- 215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3-9.
-
(2004)
J Neuroimmunol
, vol.156
, pp. 3-9
-
-
Yang, J.S.1
Xu, L.Y.2
Xiao, B.G.3
-
65
-
-
77951454321
-
Laquinimod induces up-regulation of neurotrophins in serum of patients with relapsing-remitting multiple sclerosis [abstract no. P783]
-
Linker RA, Thone J, Comi G, et al. Laquinimod induces up-regulation of neurotrophins in serum of patients with relapsing-remitting multiple sclerosis [abstract no. P783]. Mult Scler 2009; 15 (9 Suppl. 2): S237.
-
(2009)
Mult Scler
, vol.15
, Issue.9 SUPPL. 2
-
-
Linker, R.A.1
Thone, J.2
Comi, G.3
-
67
-
-
33644936033
-
Inhibition of the development of chronic experimental autoimmune en-cephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice
-
Runstrom A, Leanderson T, Ohlsson L, et al. Inhibition of the development of chronic experimental autoimmune en-cephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69-78.
-
(2006)
J Neuroimmunol
, vol.173
, pp. 69-78
-
-
Runstrom, A.1
Leanderson, T.2
Ohlsson, L.3
-
68
-
-
15244353263
-
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
-
Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treat- ment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987-91.
-
(2005)
Neurology
, vol.64
, pp. 987-91
-
-
Polman, C.1
Barkhof, F.2
Sandberg-Wollheim, M.3
-
69
-
-
0034840913
-
Suppression of ex- perimental autoimmune neuritis by leflunomide
-
Korn T, Toyka K, Hartung HP, et al. Suppression of ex- perimental autoimmune neuritis by leflunomide. Brain 2001; 124 (Pt 9): 1791-802.
-
(2001)
Brain
, vol.124
, Issue.PART 9
, pp. 1791-802
-
-
Korn, T.1
Toyka, K.2
Hartung, H.P.3
-
70
-
-
7644223637
-
Modulation of effector cell functions in experimental autoimmune encephalo-myelitis by leflunomide: Mechanisms independent of pyr-imidine depletion
-
Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalo-myelitis by leflunomide: mechanisms independent of pyr-imidine depletion. J Leukoc Biol 2004; 76: 50-60.
-
(2004)
J Leukoc Biol
, vol.76
, pp. 50-60
-
-
Korn, T.1
Magnus, T.2
Toyka, K.3
-
71
-
-
0032374063
-
Purification of human dihydro-orotate dehydrogenase and its inhibition by A77,1726, the active metabolite of leflunomide
-
Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998; 336 (Pt 2): 299-303.
-
(1998)
Biochem J
, vol.336
, Issue.PART 2
, pp. 299-303
-
-
Bruneau, J.M.1
Yea, C.M.2
Spinella-Jaegle, S.3
-
72
-
-
0029591467
-
The immuno- suppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
-
Cherwinski HM, Cohn RG, Cheung P, et al. The immuno- suppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043-9.
-
(1995)
J Pharmacol Exp Ther
, vol.275
, pp. 1043-9
-
-
Cherwinski, H.M.1
Cohn, R.G.2
Cheung, P.3
-
73
-
-
25444448197
-
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation
-
Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005; 52: 2730-9.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2730-9
-
-
Zeyda, M.1
Poglitsch, M.2
Geyeregger, R.3
-
74
-
-
0033557695
-
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
-
Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162: 2095-102.
-
(1999)
J Immunol
, vol.162
, pp. 2095-102
-
-
Manna, S.K.1
Aggarwal, B.B.2
-
75
-
-
62149096116
-
Teriflunomide re- duces behavioral, electrophysiological, and histopatholo-gical deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis
-
Merrill JE, Hanak S, Pu SF, et al. Teriflunomide re- duces behavioral, electrophysiological, and histopatholo-gical deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256: 89-103.
-
(2009)
J Neurol
, vol.256
, pp. 89-103
-
-
Merrill, J.E.1
Hanak, S.2
Pu, S.F.3
-
76
-
-
72649102197
-
The Will Rogers phenomenon: The effect of different diagnostic criteria
-
Sormani MP. The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 2009; 287 Suppl. 1: S46-9.
-
(2009)
J Neurol Sci
, vol.287
, Issue.SUPPL. 1
-
-
Sormani, M.P.1
-
77
-
-
70449722872
-
Benefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensing
-
Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32 (12): 1123-34
-
(2009)
Drug Saf
, vol.32
, Issue.12
, pp. 1123-34
-
-
Alcorn, N.1
Saunders, S.2
Madhok, R.3
|